Additionally, blockade of the renin-angiotension system may have specific benefit in those hypertensive patients with proteinuria, thus it is reasonable to initiate angiotension converting enzyme inhibitors (ACEI) or angiotension receptor blockers (ARB) as first-line therapy for anti-VEGF-targeted patients with hypertension and proteinuria [87], although this remains to be validated in randomized, controlled studies. The gene discussed is VEGFA; the disease is hypertensive disorder.